Literature DB >> 8360140

Peptidomimetic inhibitors of Ras farnesylation and function in whole cells.

A M Garcia1, C Rowell, K Ackermann, J J Kowalczyk, M D Lewis.   

Abstract

The ras protooncogene is involved in regulation of cell growth. Mutations that activate the protein result in uncontrolled cell growth. Ras undergoes a series of posttranslational processing events, the first of which, farnesylation, is crucial for the function of the protein. Inhibitors of the farnesyltransferase enzyme are therefore potential candidates for the development of anticancer drugs. Tetrapeptides have been reported to be good inhibitors of this enzyme in vitro. We have synthesized analogs of the tetrapeptide Cys-Val-Phe-Met by replacement of the amino-terminal amide bonds. One inhibitor, B581, is permeable to the cell membrane. In the cell, it inhibits processing of two farnesylated proteins, H-ras and lamin A, but it does not inhibit processing of a geranylgeranylated protein, Rap 1A. Microinjection of B581 into frog oocytes inhibits maturation induced by activated, farnesylated H-ras but not maturation induced by activated, geranylgeranylated H-ras or by progesterone. These results demonstrate that this peptide mimic inhibits farnesylation selectively in the cell. The inhibition of farnesylation results in inhibition of H-ras function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8360140

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620.

Authors:  Masanori Kurimoto; Yutaka Hirashima; Hideo Hamada; Hironaga Kamiyama; Shoichi Nagai; Nakamasa Hayashi; Shunro Endo
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

Review 3.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

4.  Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth.

Authors:  Samuel C Falsetti; De-an Wang; Hairuo Peng; Dora Carrico; Adrienne D Cox; Channing J Der; Andrew D Hamilton; Saïd M Sebti
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

5.  Mutant farnesyltransferase beta subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I beta subunit.

Authors:  H Mitsuzawa; K Esson; F Tamanoi
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  Actinoplanic acids A and B as novel inhibitors of farnesyl-protein transferase.

Authors:  K C Silverman; C Cascales; O Genilloud; J M Sigmund; S E Gartner; G E Koch; M M Gagliardi; B K Heimbuch; M Nallin-Omstead; M Sanchez
Journal:  Appl Microbiol Biotechnol       Date:  1995 Aug-Sep       Impact factor: 4.813

Review 7.  Aberrant function of the Ras signal transduction pathway in human breast cancer.

Authors:  G J Clark; C J Der
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

8.  Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation.

Authors:  S M Graham; A D Cox; G Drivas; M G Rush; P D'Eustachio; C J Der
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

9.  Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.

Authors:  G C Prendergast; J P Davide; S J deSolms; E A Giuliani; S L Graham; J B Gibbs; A Oliff; N E Kohl
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

10.  Translocation of FGF-1 and FGF-2 across vesicular membranes occurs during G1-phase by a common mechanism.

Authors:  Jedrzej Małecki; Jørgen Wesche; Camilla Skiple Skjerpen; Antoni Wiedłocha; Sjur Olsnes
Journal:  Mol Biol Cell       Date:  2003-12-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.